Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
Phase II Evaluation of Oxaliplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or refractory ovarian epithelial cancer or primary peritoneal cancer that has not responded to platinum-based chemotherapy.
調査の概要
詳細な説明
OBJECTIVES: I. Determine the antitumor activity of oxaliplatin by measuring response rate in patients with recurrent or refractory, platinum resistant ovarian epithelial or primary peritoneal carcinoma who have failed on higher priority treatment protocols. II. Determine the nature and degree of toxicity of this drug in this patient population.
OUTLINE: Patients receive oxaliplatin IV over 2 hours. Treatment continues every 21 days for a maximum of 9 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 12-14 months.
研究の種類
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006-2726
- CCOP - Greater Phoenix
-
-
California
-
Los Angeles、California、アメリカ、90033-0800
- USC/Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Orange、California、アメリカ、92868
- Chao Family Comprehensive Cancer Center
-
Palo Alto、California、アメリカ、94304
- Women's Cancer Center
-
-
Colorado
-
Denver、Colorado、アメリカ、80262
- University of Colorado Cancer Center
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20307-5000
- Walter Reed Army Medical Center
-
Washington、District of Columbia、アメリカ、20007
- Vincent T. Lombardi Cancer Research Center, Georgetown University
-
-
Florida
-
Tampa、Florida、アメリカ、33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital - Atlanta
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- MBCCOP - Hawaii
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612-7323
- MBCCOP - University of Illinois at Chicago
-
Chicago、Illinois、アメリカ、60612
- Rush-Presbyterian-St. Luke's Medical Center
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Cancer Research Center
-
Evanston、Illinois、アメリカ、60201
- CCOP - Evanston
-
Springfield、Illinois、アメリカ、62526
- CCOP - Central Illinois
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202-5265
- Indiana University Cancer Center
-
-
Iowa
-
Des Moines、Iowa、アメリカ、10309-1016
- CCOP - Iowa Oncology Research Association
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536-0084
- Albert B. Chandler Medical Center, University of Kentucky
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins Oncology Center
-
Bethesda、Maryland、アメリカ、20892
- Radiation Oncology Branch
-
Bethesda、Maryland、アメリカ、20892
- Medicine Branch
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts University School of Medicine
-
Worcester、Massachusetts、アメリカ、01655
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- CCOP - Ann Arbor Regional
-
Detroit、Michigan、アメリカ、48201
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota Cancer Center
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216-4505
- University of Mississippi Medical Center
-
Keesler AFB、Mississippi、アメリカ、39534-2576
- Keesler Medical Center - Keesler AFB
-
-
Missouri
-
Columbia、Missouri、アメリカ、65203
- Ellis Fischel Cancer Center
-
Kansas City、Missouri、アメリカ、64131
- CCOP - Kansas City
-
Saint Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
Springfield、Missouri、アメリカ、65807
- CCOP - Cancer Research for the Ozarks
-
-
Montana
-
Billings、Montana、アメリカ、59101
- CCOP - Montana Cancer Consortium
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68131
- CCOP - Missouri Valley Cancer Consortium
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- CCOP - Southern Nevada Cancer Research Foundation
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital/University Medical Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Cancer Center of Albany Medical Center
-
Brooklyn、New York、アメリカ、11203
- State University of New York Health Science Center at Brooklyn
-
Manhasset、New York、アメリカ、11030
- North Shore University Hospital
-
New York、New York、アメリカ、10021
- Memorial Sloan-Kettering Cancer Center
-
Rochester、New York、アメリカ、14642
- University of Rochester Cancer Center
-
Stony Brook、New York、アメリカ、11790-9832
- State University of New York Health Sciences Center - Stony Brook
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599-7295
- Lineberger Comprehensive Cancer Center, UNC
-
Durham、North Carolina、アメリカ、27710
- Duke Comprehensive Cancer Center
-
Winston-Salem、North Carolina、アメリカ、27157-1082
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
-
Winston-Salem、North Carolina、アメリカ、27103
- Brookview Research, Inc.
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- Barrett Cancer Center, The University Hospital
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Cancer Center
-
Cleveland、Ohio、アメリカ、44106-5065
- Ireland Cancer Center
-
Columbus、Ohio、アメリカ、43210
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73190
- University of Oklahoma College of Medicine
-
Tulsa、Oklahoma、アメリカ、74136
- CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97213
- CCOP - Columbia River Program
-
-
Pennsylvania
-
Abington、Pennsylvania、アメリカ、19001
- Abington Memorial Hospital
-
Hershey、Pennsylvania、アメリカ、17033
- Milton S. Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19111
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- Pennsylvania Hospital
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
-
Wynnewood、Pennsylvania、アメリカ、19096
- CCOP - MainLine Health
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425-0721
- Medical University of South Carolina
-
Greenville、South Carolina、アメリカ、29615
- CCOP - Greenville
-
Spartanburg、South Carolina、アメリカ、29303
- CCOP - Upstate Carolina
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38117
- CCOP - Baptist Cancer Institute
-
-
Texas
-
Dallas、Texas、アメリカ、75235-9154
- Simmons Cancer Center - Dallas
-
Houston、Texas、アメリカ、77030
- University of Texas - MD Anderson Cancer Center
-
Temple、Texas、アメリカ、76508
- CCOP - Scott and White Hospital
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- Cancer Center, University of Virginia HSC
-
-
Washington
-
Seattle、Washington、アメリカ、98195-6043
- University of Washington Medical Center
-
Tacoma、Washington、アメリカ、98405
- Tacoma General Hospital
-
-
-
-
Ontario
-
Kingston、Ontario、カナダ、K7L 3N6
- NCIC-Clinical Trials Group
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory ovarian epithelial or primary peritoneal carcinoma Bidimensionally measurable disease Ascites and pleural effusions are not considered measurable disease Sonography acceptable provided lesions are clearly defined on initial examination and bidimensionally measurable Must have had 1 prior platinum based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease Initial treatment may include high dose therapy, consolidation, or extended therapy administered after surgical or nonsurgical assessment No additional cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens Must be considered platinum resistant or refractory Treatment free interval of less than 6 months following platinum or progression during platinum based therapy No known brain metastases Must not be eligible for a higher priority GOG protocol
PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least lower limit of normal Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 2.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other: Not pregnant or nursing Fertile patients must use effective contraception No active infection requiring antibiotics No evidence of preexisting peripheral sensory neuropathy greater than grade 1, including residual neuropathy attributed to prior chemotherapy and other chronic conditions (e.g., diabetes, venous stasis, and carpal tunnel syndrome) No history of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol directed chemotherapy No other uncontrolled concurrent illness (e.g., ongoing or active infection) No other malignancy within the past 5 years except nonmelanoma skin cancer and no other prior malignancy whose prior cancer treatment contraindicates this protocol therapy
PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy At least 3 weeks since prior immunotherapy No concurrent colony stimulating factors (CSFs) during first course of therapy At least 24 hours since prior CSFs during subsequent courses of therapy Chemotherapy: See Disease Characteristics No prior oxaliplatin No more than 1 prior chemotherapy regimen If initial therapy did not include paclitaxel, a second regimen including paclitaxel is allowed At least 3 weeks since prior chemotherapy and recovered Endocrine therapy: At least 1 week since prior hormonal therapy directed at malignant tumor Concurrent continuation of hormone replacement therapy allowed Radiotherapy: At least 3 weeks since prior radiotherapy and recovered No prior radiotherapy to sites of measurable disease used on this trial No prior radiotherapy to greater than 25% of bone marrow Surgery: At least 3 weeks since prior surgery and recovered Other: No other concurrent investigational agents No concurrent antiretroviral therapy (HAART)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
協力者と研究者
捜査官
- スタディチェア:Paula M. Fracasso, MD, PhD、Washington University Siteman Cancer Center
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。